Cencora, Inc. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Cencora reported fiscal 2026 adjusted diluted EPS of $17.97 (up 12.3% YoY) on $337.4B revenue (up 5.0%). The company completed the February 2026 acquisition of OneOncology for an undisclosed amount, financed with $3.0B senior notes and $1.5B term loans, which contributed to gross profit growth of 20.0% but was offset by 23.7% operating expense growth. FY2027 adjusted EPS guidance of $19.40–$19.75 (8–10% growth) and a 10% quarterly dividend increase to $0.66/share were announced. Segment restructuring effective Q1 FY2027 reorganizes reporting into Pharmaceutical Distribution & Services and Specialty Pharmaceutical & Provider Services.
Why this rating
OneOncology acquisition and margin expansion are material, but organic revenue growth (5%) is modest; guidance reflects steady (8–10%) EPS growth. Relative to $37.9B market cap, changes are meaningful but not transformational. Restructuring and dividend increase are shareholder-friendly but routine.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.